Daiichi Sankyo Generics Entry Could Help Japan's Branded Generics Makers
This article was originally published in PharmAsia News
Executive Summary
Following Pfizer's step, Daiichi Sankyo is venturing into the generic drug business in Japan. The third-largest domestic branded drug maker Feb. 26 announced the establishment of generic subsidiary Daiichi Sankyo Espha, and a plan to start marketing products beginning in October. The announcement has stirred up a shock wave across the industry
You may also be interested in...
Merck Eyes Emerging Biosimilars Market In Japan
Merck is the latest major drug maker to leap into the Japanese generics foray, as the Whitehouse Station, NJ-based company announced plans to launch its first biosimilar drug for anemia in Japan as early as 2012
Merck Eyes Emerging Biosimilars Market In Japan
Merck is the latest major drug maker to leap into the Japanese generics foray, as the Whitehouse Station, NJ-based company announced plans to launch its first biosimilar drug for anemia in Japan as early as 2012
Merck Eyes Emerging Biosimilars Market In Japan
The company's Japanese subsidiary Banyu Pharmaceutical has started domestic trials for its generic erythropoietin, poised to be Merck's first biosimilar launch.